GDC-1971 (Not yet branded)

Other Medications

US Experimental EU Experimental ES med_spain_not_available Oral 2 Clinical Trials
SOS1

Description

GDC-1971 is a SOS1 (Son of Sevenless 1) inhibitor being developed for treatment of advanced solid tumors, including colorectal cancer with KRAS mutations. This targeted therapy is designed to block the SOS1 protein, which plays a crucial role in activating mutant KRAS signaling pathways that drive tumor growth. The drug is being evaluated in combination with other targeted agents like osimertinib in patients with unresectable or metastatic disease.

Mechanism of Action

GDC-1971 works by selectively inhibiting SOS1, a guanine nucleotide exchange factor that is essential for KRAS activation. By blocking SOS1, the drug prevents the formation of active KRAS-GTP complexes, thereby disrupting downstream oncogenic signaling pathways including RAF-MEK-ERK and PI3K-AKT that promote cancer cell proliferation and survival.

Molecular Targets

Side Effects

Fatigue Nausea Diarrhea Decreased appetite Skin rash Elevated liver enzymes Low white blood cell count Muscle weakness

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05954871 med_phase_prefix1
Completed
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastati
United States, Australia, South Korea
NCT04449874 med_phase_prefix1
Active, not recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
United States, Australia, Belgium, Brazil, Canada, Hungary, Israel, Italy, Kenya

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
AdministrationOral
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.